Skip to content

Study · Animal study (in vivo) · mouse · 2020

16 results

Site-Specific and Temporal Effects of Apraglutide, a Novel Long-Acting Glucagon-Like Peptide-2 Receptor Agonist, on Intestinal Growth in Mice.

Martchenko SE, Sweeney ME, Dimitriadou V, Murray JA, Brubaker PL

The Journal of pharmacology and experimental therapeutics6 Mar 2020Cited by 10 (Europe PMC)

PMID32144124 (opens in a new tab)DOI10.1124/jpet.119.263947 (opens in a new tab)PepBankPUB-32144124
Source linkPubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased small-intestinal weight after 3 weeks.

    In plain wordsIn mice, apraglutide increased small-intestinal weight after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseSmall-intestinal weight
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Apraglutide (3 mg/kg; three times per week) significantly increased small intestinal weight (P P P < 0.01).
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased small-intestinal length after 3 weeks.

    In plain wordsIn mice, apraglutide increased small-intestinal length after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseSmall-intestinal length
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Apraglutide (3 mg/kg; three times per week) significantly increased small intestinal weight (P P P < 0.01).
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide's effect on small-intestinal weight increased further after 10 weeks.

    In plain wordsIn mice, apraglutide's effect on small-intestinal weight increased further after 10 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseSmall-intestinal weight with longer treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Apraglutide (3 mg/kg; three times per week) significantly increased small intestinal weight (P P P < 0.01).
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide's effect on small-intestinal length increased further after 10 weeks.

    In plain wordsIn mice, apraglutide's effect on small-intestinal length increased further after 10 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseSmall-intestinal length with longer treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Apraglutide (3 mg/kg; three times per week) significantly increased small intestinal weight (P P P < 0.01).
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased crypt depth after 3 weeks.

    In plain wordsIn mice, apraglutide increased intestinal crypt depth after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseCrypt depth
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Crypt depth and villus height were both markedly increased after 3 weeks of apraglutide administration (P < 0.001) but did not show any further increase with duration of treatment,
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased villus height after 3 weeks.

    In plain wordsIn mice, apraglutide increased intestinal villus height after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseVillus height
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Crypt depth and villus height were both markedly increased after 3 weeks of apraglutide administration (P < 0.001) but did not show any further increase with duration of treatment,
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice, crypt depth did not increase further with longer apraglutide treatment.

    In plain wordsIn mice, intestinal crypt depth did not increase further with longer apraglutide treatment.

    Peptide
    Apraglutide
    Outcome
    No significant changeCrypt depth with longer treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per weekAs given in this study (mouse).

    Source sentences

    Summary
    Crypt depth and villus height were both markedly increased after 3 weeks of apraglutide administration (P < 0.001) but did not show any further increase with duration of treatment,
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, villus height did not increase further with longer apraglutide treatment.

    In plain wordsIn mice, intestinal villus height did not increase further with longer apraglutide treatment.

    Peptide
    Apraglutide
    Outcome
    No significant changeVillus height with longer treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per weekAs given in this study (mouse).

    Source sentences

    Summary
    Crypt depth and villus height were both markedly increased after 3 weeks of apraglutide administration (P < 0.001) but did not show any further increase with duration of treatment,
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased crypt number after 7 and 10 weeks.

    In plain wordsIn mice, apraglutide increased intestinal crypt number after 7 and 10 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseCrypt number
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 7 and 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    whereas crypt number and intestinal circumference were increased after 7 and 10 weeks (P < 0.01) but not after 3 weeks of apraglutide treatment.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased intestinal circumference after 7 and 10 weeks.

    In plain wordsIn mice, apraglutide increased intestinal circumference after 7 and 10 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseIntestinal circumference
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 7 and 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    whereas crypt number and intestinal circumference were increased after 7 and 10 weeks (P < 0.01) but not after 3 weeks of apraglutide treatment.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide did not increase crypt number after 3 weeks.

    In plain wordsIn mice, apraglutide did not increase intestinal crypt number after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    No significant changeCrypt number at early treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    whereas crypt number and intestinal circumference were increased after 7 and 10 weeks (P < 0.01) but not after 3 weeks of apraglutide treatment.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide did not increase intestinal circumference after 3 weeks.

    In plain wordsIn mice, apraglutide did not increase intestinal circumference after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    No significant changeIntestinal circumference at early treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    whereas crypt number and intestinal circumference were increased after 7 and 10 weeks (P < 0.01) but not after 3 weeks of apraglutide treatment.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased colon weight after 3 weeks.

    In plain wordsIn mice, apraglutide increased colon weight after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseColon weight
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Both the weight and the length of the colon were also enhanced by apraglutide treatment for 3 weeks (P < 0.001), and these effects were maintained but did not improve further with continued apraglutide administration.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide increased colon length after 3 weeks.

    In plain wordsIn mice, apraglutide increased colon length after 3 weeks.

    Peptide
    Apraglutide
    Outcome
    IncreaseColon length
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per week · 3 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Both the weight and the length of the colon were also enhanced by apraglutide treatment for 3 weeks (P < 0.001), and these effects were maintained but did not improve further with continued apraglutide administration.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide's colon weight effect persisted without further improvement during continued treatment.

    In plain wordsIn mice, apraglutide's effect on colon weight persisted without further improvement during continued treatment.

    Peptide
    Apraglutide
    Outcome
    No significant changeColon weight with continued treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per weekAs given in this study (mouse).

    Source sentences

    Summary
    Both the weight and the length of the colon were also enhanced by apraglutide treatment for 3 weeks (P < 0.001), and these effects were maintained but did not improve further with continued apraglutide administration.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In mice, apraglutide's colon length effect persisted without further improvement during continued treatment.

    In plain wordsIn mice, apraglutide's effect on colon length persisted without further improvement during continued treatment.

    Peptide
    Apraglutide
    Outcome
    No significant changeColon length with continued treatment
    Study

    mousen: not reported in source

    male and female mice
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    3 mg/kg three times per weekAs given in this study (mouse).

    Source sentences

    Summary
    Both the weight and the length of the colon were also enhanced by apraglutide treatment for 3 weeks (P < 0.001), and these effects were maintained but did not improve further with continued apraglutide administration.
    1 context sentence
    Summary · context
    The present study examined the effects of apraglutide, a novel GLP-2R agonist, on the growth of the small intestine and colon after 3, 7, and 10 weeks of treatment in male and female mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.